HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Feasibility of intraperitoneal Trastuzumab treatment in a patient with peritoneal carcinomatosis from gastric cancer.

AbstractOBJECTIVES:
This case report evaluates the feasibility and efficacy of intraperitoneal (IP) trastuzumab administration in gastric cancer (GC) patients with peritoneal carcinomatoses.
METHODS:
Peritoneal metastasis is a common sign of advanced tumor stage, tumor progression or disease recurrence in patients with GC. Recently, the role of HER2 overexpression in GC, occurring in about 20% of cases, is correlated with a worse prognosis. We report the case of 61-years old female, admitted to our Hospital after curative surgery for GC with over-expression of HER2. Seven months after the start of first line chemotherapy treatment a pleuro-peritoneal disease progression occurred, documented by cytological exam; according to HER2 status, we decided to treat the patient with IP trastuzumab administration.
RESULTS:
Between September and October 2012, the patient (ECOG performance status was 0), underwent to 6 cycles of IP trastuzumab. Trastuzumab was administered weekly at a dose of 150 mg for each cycle after paracentesis. The safety was good, no local complications (e.g. abdominal pain, peritonitis) occurred. The clinical revaluation evidenced a stable peritoneal disease.
CONCLUSIONS:
To our knowledge this is the first report on Trastuzumab use to treat IP metastases from GC, with acceptable toxicity and local disease control.
AuthorsM Berretta, R Fisichella, E Borsatti, A Lleshi, S Ioffredo, N Meneguzzo, V Canzonieri, A Di Grazia, R Cannizzaro, U Tirelli, S Berretta
JournalEuropean review for medical and pharmacological sciences (Eur Rev Med Pharmacol Sci) Vol. 18 Issue 5 Pg. 689-92 ( 2014) ISSN: 2284-0729 [Electronic] Italy
PMID24668709 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Trastuzumab
Topics
  • Antineoplastic Agents (administration & dosage)
  • Carcinoma
  • Feasibility Studies
  • Female
  • Humans
  • Injections, Intraperitoneal
  • Middle Aged
  • Neoplasm Recurrence, Local (pathology)
  • Peritoneal Neoplasms (diagnosis, drug therapy, secondary)
  • Stomach Neoplasms (diagnosis, drug therapy)
  • Trastuzumab (administration & dosage)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: